Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

The Affordable Health Care Act annual wellness visits: the effectiveness of a nurse-run clinic in promoting adherence to mammogram and colonoscopy recommendations.

Tetuan TM, Ohm R, Herynk MH, Ebberts M, Wendling T, Mosier MC.

J Nurs Adm. 2014 May;44(5):270-5. doi: 10.1097/NNA.0000000000000066.

PMID:
24759199
2.

Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells.

Selever J, Gu G, Lewis MT, Beyer A, Herynk MH, Covington KR, Tsimelzon A, Dontu G, Provost P, Di Pietro A, Boumendjel A, Albain K, Miele L, Weiss H, Barone I, Ando S, Fuqua SA.

Clin Cancer Res. 2011 Oct 15;17(20):6510-21. doi: 10.1158/1078-0432.CCR-11-1403. Epub 2011 Aug 30.

3.

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.

Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, Xu L, Herynk MH, McKee KS, Tran HT, Logothetis CJ, Tannir NM, Heymach JV.

Ann Oncol. 2012 Jan;23(1):46-52. doi: 10.1093/annonc/mdr047. Epub 2011 Apr 4.

4.

Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.

Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, Oborn CJ, Park YY, Erez B, Jacoby JJ, Lee JS, Lin HY, Ciardiello F, Herbst RS, Langley RR, Heymach JV.

J Clin Invest. 2011 Apr;121(4):1313-28. doi: 10.1172/JCI42405. Epub 2011 Mar 23.

5.

Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells.

Xu L, Nilsson MB, Saintigny P, Cascone T, Herynk MH, Du Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson FM, Wong KK, Girard L, Gazdar AF, Minna JD, Kurie JM, Wistuba II, Heymach JV.

Oncogene. 2010 May 6;29(18):2616-27. doi: 10.1038/onc.2010.16. Epub 2010 Feb 15.

6.

A hypersensitive estrogen receptor alpha mutation that alters dynamic protein interactions.

Herynk MH, Hopp T, Cui Y, Niu A, Corona-Rodriguez A, Fuqua SA.

Breast Cancer Res Treat. 2010 Jul;122(2):381-93. doi: 10.1007/s10549-009-0580-1. Epub 2009 Oct 20.

7.

Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation.

Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, Woods DM, Tang X, Mehran RJ, Moran C, Lee JJ, Wistuba II.

Clin Cancer Res. 2009 Sep 1;15(17):5359-68. doi: 10.1158/1078-0432.CCR-09-0033. Epub 2009 Aug 25.

8.

Accelerated mammary maturation and differentiation, and delayed MMTVneu-induced tumorigenesis of K303R mutant ERalpha transgenic mice.

Herynk MH, Lewis MT, Hopp TA, Medina D, Corona-Rodriguez A, Cui Y, Beyer AR, Fuqua SA.

Oncogene. 2009 Sep 10;28(36):3177-87. doi: 10.1038/onc.2009.174. Epub 2009 Jun 29.

9.

Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells.

De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, Weigel NL, Herynk MH, Tsimelzon A, Lewis MT, Chamness GC, Hilsenbeck SG, Andò S, Fuqua SA.

Breast Cancer Res Treat. 2010 May;121(1):1-11. doi: 10.1007/s10549-009-0436-8. Epub 2009 Jun 17.

10.

Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway.

Barone I, Cui Y, Herynk MH, Corona-Rodriguez A, Giordano C, Selever J, Beyer A, Andò S, Fuqua SA.

Cancer Res. 2009 Jun 1;69(11):4724-32. doi: 10.1158/0008-5472.CAN-08-4194.

11.

Hormone Action and Clinical Significance of the Estrogen Receptor α.

Herynk MH, Selever J, Thirugnanasampanthan J, Cui Y, Fuqua SA.

Cancer Treat Res. 2009;147:1-16. No abstract available.

PMID:
21461833
12.

Estrogen receptors in resistance to hormone therapy.

Herynk MH, Fuqua SA.

Adv Exp Med Biol. 2007;608:130-43. Review.

PMID:
17993238
13.

Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells.

Herynk MH, Zhang J, Parikh NU, Gallick GE.

J Exp Ther Oncol. 2007;6(3):205-17.

PMID:
17552361
14.

Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer.

Herynk MH, Parra I, Cui Y, Beyer A, Wu MF, Hilsenbeck SG, Fuqua SA.

Clin Cancer Res. 2007 Jun 1;13(11):3235-43.

15.

Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.

Herynk MH, Beyer AR, Cui Y, Weiss H, Anderson E, Green TP, Fuqua SA.

Mol Cancer Ther. 2006 Dec;5(12):3023-31.

16.
17.

Estrogen receptor mutations in human disease.

Herynk MH, Fuqua SA.

Endocr Rev. 2004 Dec;25(6):869-98. Review.

PMID:
15583021
19.

Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin.

Herynk MH, Tsan R, Radinsky R, Gallick GE.

Clin Exp Metastasis. 2003;20(4):291-300.

PMID:
12856716
20.

Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells.

Herynk MH, Stoeltzing O, Reinmuth N, Parikh NU, Abounader R, Laterra J, Radinsky R, Ellis LM, Gallick GE.

Cancer Res. 2003 Jun 1;63(11):2990-6.

21.

Supplemental Content

Loading ...
Support Center